Advaxis Shares Up 40.2% Premarket After FDA Lifted Clinical Hold On Co.'s Investigational New Drug Axalimogene Filolisbic (AXAL); Hold Was Issued March 9 After Co. Submitted Safety Report to FDA Regarding Patient Death In Individual Treated With AXAL